FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding
This article was originally published in The Tan Sheet
Executive Summary
The Medicare prescription drug coverage legislation should help FDA make the case for additional funding for post-marketing surveillance, according to Center for Drug Evaluation & Research Acting Director Steven Galson, MD
You may also be interested in...
CDER Deputy Galson Will Run Drug Center For At Least Six Months
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands